Ipsen Pharma conducted a buy-back program from June 15 to June 19, 2026, purchasing a total of 28,105 of its own shares. The daily average purchase price ranged around €155 to €157 per share on the Euronext Paris market. This buy-back is part of Ipsen's ongoing strategy to manage its capital and potentially support its stock price. Investors should watch for further updates on the program and its impact on Ipsen's share value and capital structure.
Ipsen Pharma conducted a buy-back of 28,105 of its own shares during the week of June 15 to June 19, 2026. The purchases were made daily on the XPAR market at an average price of approximately €156.21 per share, in compliance with Article 5 of the MA...
In May 2026, New York State's housing inventory increased by 3.2% year-over-year to 30,489 homes, marking the 15th consecutive month of growth. Pending sales rose 5.6%, indicating stronger buyer interest as the summer season began. However, closed sa...
Grabar Law Office is investigating potential breaches of fiduciary duties by officers and directors at Badger Meter, GeneDx Holdings, GRAIL, and Verra Mobility. These investigations follow allegations that these companies made false or misleading sta...
iQor has launched a new customer experience delivery center in New Cairo, Egypt, starting with 500 seats and aiming to expand to 5,000 employees over five years. This move is supported by the Egyptian government through partnerships with ITIDA and MC...
Crédit Agricole Brie Picardie conducted share buybacks totaling 22,829 shares from June 15 to June 19, 2026, with daily volumes ranging from 2,147 to 6,656 shares at prices between €36.75 and €37.79. These repurchases were made in compliance with Art...
